Retatrutide benefits for women are generating significant interest as this investigational triple receptor agonist advances through Phase 3 clinical trials. Developed by Eli Lilly, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors — a mechanism that may offer advantages for weight management, metabolic health, and conditions such as polycystic ovary syndrome (PCOS) that disproportionately affect women. Early Phase 2 data show promising results, yet retatrutide remains unlicensed in the UK. This article outlines what the current evidence suggests, key safety considerations for women, and what to discuss with your GP.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly injectable triple receptor agonist activating GLP-1, GIP, and glucagon receptors to reduce appetite, improve insulin secretion, and increase energy expenditure. It is not yet licensed by the MHRA or EMA.

Retatrutide is an investigational medicine currently under clinical development for the treatment of obesity and related metabolic conditions. It belongs to a novel class of drugs known as triple receptor agonists, meaning it simultaneously activates three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 receptor agonist).

By activating the GLP-1 receptor, retatrutide is thought to help reduce appetite, slow gastric emptying, and improve insulin secretion in a glucose-dependent manner. The GIP receptor component is believed to enhance metabolic and weight-loss effects, whilst glucagon receptor activation is hypothesised to increase energy expenditure and promote hepatic fat breakdown (lipolysis). These proposed complementary mechanisms are supported by early-phase human data, though the precise contribution of each receptor pathway in clinical practice has not yet been fully established.

Retatrutide is administered as a once-weekly subcutaneous injection, similar in delivery to other agents in this drug class. It is being developed by Eli Lilly and Company and is currently in Phase 3 clinical trials (registered on ClinicalTrials.gov). It has not yet received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and therefore remains unavailable as a licensed treatment in the UK at this time. Understanding its proposed mechanism provides useful context for evaluating the potential benefits it may offer, particularly for women living with obesity or metabolic disorders.

Potential Benefits of Retatrutide for Women

Retatrutide may benefit women through substantial weight loss and improvements in cardiovascular risk markers, with theoretical utility in PCOS and MASLD, though no condition-specific trials in women have been published.

The potential benefits of retatrutide for women are broad, spanning weight management, metabolic health, and conditions that disproportionately affect females. The most prominent benefit observed in trials is substantial body weight reduction. For women living with obesity — a condition associated with increased risk of type 2 diabetes, cardiovascular disease, certain cancers, and joint problems — achieving meaningful and sustained weight loss can significantly improve overall health outcomes and quality of life.

Beyond weight loss, retatrutide's glucagon receptor activity may theoretically offer advantages for women with metabolic dysfunction-associated steatotic liver disease (MASLD, previously termed non-alcoholic fatty liver disease or NAFLD) or its more severe form, metabolic dysfunction-associated steatohepatitis (MASH, previously NASH). These conditions are increasingly prevalent in women, particularly after the menopause. Based on the known effects of GLP-1 and glucagon receptor agonism on hepatic fat metabolism and insulin sensitivity, there is a plausible mechanistic rationale for benefit; however, no dedicated retatrutide trials in this population have been published, and any such benefit remains unproven for this specific medicine.

Women with polycystic ovary syndrome (PCOS) represent another group who may potentially benefit. PCOS is closely linked to insulin resistance and excess body weight, and weight loss achieved through pharmacological intervention has been shown to improve hormonal balance, menstrual regularity, and fertility outcomes in studies of GLP-1-based therapies. Whilst no specific PCOS trials for retatrutide have been published, the mechanistic overlap with existing GLP-1-based therapies provides a theoretical basis for potential utility. This should not be interpreted as evidence of proven benefit for retatrutide in PCOS.

Improvements in cardiovascular risk markers — including blood pressure, triglycerides, and HbA1c — were observed in the Phase 2 trial (Jastreboff et al., NEJM, 2023), all of which are clinically relevant for women, particularly those in midlife and beyond. These are promising early findings; however, definitive conclusions await the completion of larger, longer-term Phase 3 studies.

Clinical Trial Evidence and Findings in Female Participants

Phase 2 trial data (Jastreboff et al., NEJM, 2023) showed dose-dependent weight reduction and metabolic improvements, but sex-disaggregated results were not published, so female-specific efficacy cannot yet be confirmed.

The most significant clinical evidence for retatrutide to date comes from a Phase 2 randomised, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.). This study enrolled adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. Participants received varying doses of retatrutide or placebo over 24 weeks, with results demonstrating notable weight loss across all active treatment groups.

At the highest dose studied (12 mg), participants achieved a mean body weight reduction of approximately 17.5% at 24 weeks. It is important to note that no head-to-head trials comparing retatrutide directly with semaglutide or tirzepatide have been conducted; cross-trial comparisons are not appropriate given differences in study design, populations, and timepoints, and no superiority claims can be made on this basis.

Whilst women were represented in the trial population, the published data did not present fully disaggregated sex-specific results. The overall findings are therefore considered broadly applicable across sexes, but whether women experience differential efficacy or tolerability compared to men cannot be determined from currently available data.

Key findings from the Phase 2 trial included:

• Dose-dependent reductions in body weight across all active treatment arms

• Significant improvements in waist circumference, a key marker of visceral adiposity

• Reductions in fasting insulin levels and HbA1c

• Improvements in lipid profiles, including triglycerides

Phase 3 trials are currently ongoing and are expected to include larger, more diverse populations with more granular subgroup analyses, including sex-specific data. These trials will be critical in establishing the full efficacy and safety profile of retatrutide. Until these results are available and regulatory review is complete, the evidence base, whilst promising, should be interpreted with appropriate caution.

Hormonal and Metabolic Considerations for Women

Women face distinct hormonal factors — including menopause and PCOS — that may influence retatrutide's effects, but no dedicated studies in these groups exist; women planning pregnancy should stop treatment before conceiving.

Women experience distinct hormonal transitions throughout their lives — including puberty, pregnancy, and the menopause — each of which can significantly influence body weight, fat distribution, and metabolic function. These physiological differences mean that weight management interventions may interact with female biology in ways that require specific consideration.

During the perimenopausal and postmenopausal periods, declining oestrogen levels are associated with increased central adiposity, insulin resistance, and a higher risk of metabolic syndrome. Retatrutide's proposed ability to target multiple metabolic pathways simultaneously may be relevant for this demographic; however, no studies have yet examined retatrutide's effects in postmenopausal women as a distinct cohort, and any specific benefits in this group remain unproven.

For women of reproductive age, the relationship between GLP-1 receptor agonists and reproductive hormones is an area of active research. Evidence from studies of existing GLP-1-based therapies suggests that weight loss can improve hormonal profiles in women with PCOS, including reductions in androgen levels and improvements in ovulatory function. Whether retatrutide's additional glucagon and GIP receptor activity confers further hormonal benefits remains to be established in dedicated studies.

Important safety information for women of childbearing potential:

Use of retatrutide during pregnancy or breastfeeding is not recommended. Based on UK prescribing information for licensed medicines in related drug classes, women planning a pregnancy should discontinue treatment before attempting to conceive. The recommended washout period differs by product: the UK Summary of Product Characteristics (SmPC) for semaglutide (Wegovy) advises stopping treatment at least two months before a planned pregnancy, whilst the SmPC for tirzepatide (Mounjaro) advises stopping at least one month before. Equivalent guidance for retatrutide will be established upon licensing.

Women using oral contraceptives should also be aware that tirzepatide has been shown to reduce exposure to oral contraceptive hormones; the Mounjaro SmPC advises using additional barrier contraception during the first four weeks of treatment and for four weeks after each dose increase. Whilst this interaction has not been studied for retatrutide, women should discuss contraception with their GP or specialist before starting any medicine in this drug class.

All women should discuss their reproductive health status, contraception, and family planning with their GP or a specialist before commencing any therapy in this drug class.

Safety Profile, Side Effects, and Guidance

The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhoea; serious risks include pancreatitis, gallbladder disease, and dehydration, consistent with the GLP-1 receptor agonist drug class.

As retatrutide has not yet received MHRA or EMA approval, there is no official UK prescribing information or regulatory safety guidance specific to this medicine at present. The safety data available derive from Phase 2 clinical trials (Jastreboff et al., NEJM, 2023), which, whilst informative, represent a relatively limited population and duration of follow-up compared to post-marketing surveillance.

The most commonly reported side effects in the Phase 2 trial were gastrointestinal in nature, consistent with the broader GLP-1 receptor agonist drug class. These included:

• Nausea — the most frequently reported adverse effect, particularly during dose escalation

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects were generally mild to moderate in severity and tended to diminish over time. Dose escalation protocols used in trials were designed to minimise gastrointestinal tolerability issues.

Based on the known class profile of GLP-1 and glucagon receptor agonists, the following additional risks are relevant:

• Pancreatitis: Severe and persistent abdominal pain, particularly if it radiates to the back and is accompanied by vomiting, may indicate pancreatitis. Anyone experiencing these symptoms should seek urgent medical attention and stop treatment until assessed.

• Gallbladder disease: Rapid weight loss is associated with an increased risk of gallstones and gallbladder inflammation (cholecystitis). Right upper quadrant pain, fever, or jaundice should prompt urgent medical review.

• Dehydration: Severe gastrointestinal side effects can lead to dehydration and, in some cases, acute kidney injury. If you are unable to maintain adequate fluid intake, seek medical advice promptly.

• Heart rate: A small increase in resting heart rate has been observed with medicines in this class.

• Hypoglycaemia: When used alongside insulin or sulfonylureas, there is an increased risk of low blood sugar. This should be discussed with your prescriber.

Regarding thyroid safety: animal studies with GLP-1 receptor agonists have identified thyroid C-cell changes in rodents; however, the clinical relevance of this finding in humans is uncertain, and this is not listed as a contraindication in UK or EU Summaries of Product Characteristics for licensed medicines in this class. Women with a personal or family history of thyroid conditions should discuss this with their doctor.

Women should not attempt to access retatrutide through unregulated online sources, as unlicensed products carry significant safety risks. Suspected side effects from any licensed medicine in this class should be reported via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk/.

Current Availability and What to Discuss With Your GP

Retatrutide is not licensed in the UK and cannot be legally prescribed outside clinical trials; women should discuss existing NICE-approved options such as semaglutide (Wegovy) or tirzepatide (Mounjaro) with their GP.

Retatrutide is not currently available as a licensed medicine in the United Kingdom. It remains in Phase 3 clinical development, and regulatory submissions to the MHRA and EMA have not yet been completed. As such, it cannot be legally prescribed or dispensed through NHS or private healthcare channels in the UK at this time. Women who have read about retatrutide online or in the media should be aware that any products claiming to be retatrutide sold outside of regulated clinical trials are unlicensed and potentially unsafe.

For women seeking support with weight management or related metabolic conditions now, there are several NICE-approved options available. NICE Technology Appraisal TA875 supports the use of semaglutide 2.4 mg (Wegovy) for weight management in eligible adults, and a corresponding NICE Technology Appraisal supports the use of tirzepatide (Mounjaro) for weight management. Both medicines are recommended for use within specialist weight management services (Tier 3 or Tier 4), and eligibility criteria apply — including BMI thresholds and the presence of weight-related comorbidities. Your GP can assess your eligibility and refer you to appropriate services, which may include dietary support, behavioural interventions, and pharmacotherapy.

If you are interested in participating in clinical research involving retatrutide or other investigational medicines, the NIHR's Be Part of Research platform (bepartofresearch.nihr.ac.uk) is the recommended UK resource for finding and joining clinical trials.

When speaking with your GP, it may be helpful to discuss:

• Your current BMI and any weight-related health conditions

• Whether you meet the criteria for existing licensed weight management medications

• Your reproductive health status, contraception, and any plans for pregnancy

• Any personal or family history of thyroid disease, pancreatitis, or gallbladder problems

• Your interest in clinical trials, should you wish to explore participation in retatrutide research

Staying informed about emerging treatments is entirely reasonable, but it is important to do so through reliable sources such as the NHS website (nhs.uk), NICE (nice.org.uk), and the MHRA (gov.uk/mhra). Your GP or a specialist in endocrinology or obesity medicine is best placed to advise you on the most appropriate and evidence-based treatment pathway for your individual circumstances.

Frequently Asked Questions